Could a simple drug switch stop MS symptoms from returning?
NCT ID NCT07389590
First seen Feb 05, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study looks at whether switching from ocrelizumab to ublituximab can help people with multiple sclerosis (MS) who experience a return of symptoms before their next dose. About 50 adults with relapsing MS who have been on ocrelizumab for at least a year and notice this 'wearing off' effect will be enrolled. Researchers will track symptom changes using quality-of-life surveys to see if the switch improves or delays symptom return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.